AAAAAA

   
Results: 1-14 |
Results: 14
Combined copy status of 18q21 genes in colorectal cancer shows frequent retention of SMAD7
Authors: Boulay, JL Mild, G Reuter, J Lagrange, M Terracciano, L Lowy, A Laffer, U Orth, B Metzger, U Stamm, B Martinoli, S Herrmann, R Rochlitz, C
Citation: Jl. Boulay et al., Combined copy status of 18q21 genes in colorectal cancer shows frequent retention of SMAD7, GENE CHROM, 31(3), 2001, pp. 240-247
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study
Authors: Schuler, M Herrmann, R De Greve, JLP Stewart, AK Gatzemeier, U Stewart, DJ Laufman, L Gralla, R Kuball, J Buhl, R Heussel, CP Kommoss, F Perruchoud, AP Shepherd, FA Fritz, MA Horowitz, JA Huber, C Rochlitz, C
Citation: M. Schuler et al., Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study, J CL ONCOL, 19(6), 2001, pp. 1750-1758
Metastatic primitive neuroectodermal tumor of the kidney in adults
Authors: Casella, R Moch, H Rochlitz, C Meier, V Seifert, B Mihatsch, MJ Gasser, TC
Citation: R. Casella et al., Metastatic primitive neuroectodermal tumor of the kidney in adults, EUR UROL, 39(5), 2001, pp. 613-617
P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients
Authors: Boulay, JL Perruchoud, AP Reuter, J Bolliger, C Herrmann, R Rochlitz, C
Citation: Jl. Boulay et al., P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients, CANC GENE T, 7(9), 2000, pp. 1215-1219
Combined chemoradiotherapy with daily low-dose cisplatin in locally advanced inoperable non-small cell lung cancer
Authors: Biedermann, B Landmann, C Kann, R Passweg, J Soler, M Lohri, A Rochlitz, C Herrmann, R Pless, M
Citation: B. Biedermann et al., Combined chemoradiotherapy with daily low-dose cisplatin in locally advanced inoperable non-small cell lung cancer, RADIOTH ONC, 56(2), 2000, pp. 169-173
Locally inducible CD66a (CEACAM1) as an amplifier of the human intestinal T cell response
Authors: Donda, A Mori, L Shamshiev, A Carena, I Mottet, C Heim, MH Beglinger, C Grunert, F Rochlitz, C Terracciano, L Jantscheff, P De Libero, G
Citation: A. Donda et al., Locally inducible CD66a (CEACAM1) as an amplifier of the human intestinal T cell response, EUR J IMMUN, 30(9), 2000, pp. 2593-2603
Phase I clinical trial with IL-2-transfected xenogeneic cells administeredin subcutaneous metastatic tumours: clinical and immunological findings
Authors: Tartour, E Mehtali, M Sastre-Garau, X Joyeux, I Mathiot, C Pleau, J Squiban, P Rochlitz, C Courtney, M Jantscheff, P Herrmann, R Pouillart, P Fridman, WH Dorval, T
Citation: E. Tartour et al., Phase I clinical trial with IL-2-transfected xenogeneic cells administeredin subcutaneous metastatic tumours: clinical and immunological findings, BR J CANC, 83(11), 2000, pp. 1454-1461
Cancer gene and immunotherapy: recent developments
Authors: Jantscheff, P Herrmann, R Rochlitz, C
Citation: P. Jantscheff et al., Cancer gene and immunotherapy: recent developments, MED ONCOL, 16(2), 1999, pp. 78-85
CT-guided intratumoral gene therapy in non-small-cell lung cancer
Authors: Kauczor, HU Schuler, M Heussel, CP von Weymarn, A Bongartz, G Rochlitz, C Huber, C Thelen, M
Citation: Hu. Kauczor et al., CT-guided intratumoral gene therapy in non-small-cell lung cancer, EUR RADIOL, 9(2), 1999, pp. 292-296
Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors
Authors: Rochlitz, C Jantscheff, P Bongartz, G Dietrich, PY Quiquerez, AL Schatz, C Mehtali, M Courtney, M Tartour, E Dorval, T Fridman, WH Herrmann, R
Citation: C. Rochlitz et al., Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors, CANC GENE T, 6(3), 1999, pp. 271-281
Axl expression is associated with adverse prognosis and with expression ofBcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK)
Authors: Rochlitz, C Lohri, A Bacchi, M Schmidt, M Nagel, S Fopp, M Fey, MF Herrmann, R Neubauer, A
Citation: C. Rochlitz et al., Axl expression is associated with adverse prognosis and with expression ofBcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK), LEUKEMIA, 13(9), 1999, pp. 1352-1358
Gene dosage by quantitative real-time PCR
Authors: Boulay, JL Reuter, J Ritschard, R Terracciano, L Herrmann, R Rochlitz, C
Citation: Jl. Boulay et al., Gene dosage by quantitative real-time PCR, BIOTECHNIQU, 27(2), 1999, pp. 228
Gene therapy with cytokine-transfected xenogenic cells (Vero-IL-2) in patients with metastatic solid tumors: mechanism(s) of elimination of the transgene-carrying cells
Authors: Jantscheff, P Herrmann, R Spagnoli, G Reuter, J Mehtali, M Courtney, M Rochlitz, C
Citation: P. Jantscheff et al., Gene therapy with cytokine-transfected xenogenic cells (Vero-IL-2) in patients with metastatic solid tumors: mechanism(s) of elimination of the transgene-carrying cells, CANCER IMMU, 48(6), 1999, pp. 321-330
Burned-out tumour of the testis: a rare form of a germ-cell neoplasm
Authors: Casella, R Rochlitz, C Sauter, G Gasser, TC
Citation: R. Casella et al., Burned-out tumour of the testis: a rare form of a germ-cell neoplasm, SCHW MED WO, 129(6), 1999, pp. 235-240
Risultati: 1-14 |